Skip to main content
SpringerLink
Log in

Looking into the Future—The EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogren’s Syndrome

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1502 Accesses

Abstract

In primary Sjögren’s syndrome (SS), clinical features can be divided into two facets: the benign subjective but disabling manifestations such as dryness, articular and muscular pain, and fatigue, and the systemic manifestations such as synovitis, vasculitis, skin, lung, renal and neurological involvement, or lymphoma. Great efforts have been made to develop valid activity indexes needed to assess the effectiveness of new therapies. First, for evaluation of patients’ symptoms: the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI) then for systemic features: the SS Disease Activity Index (SSDAI) and Sjögren’s Systemic Clinical Activity Index (SCAI). The development of these indexes served as bases of an international collaborative project promoted by European League Against Rheumatism (EULAR). Thirty-nine primary SS experts were involved in the development of these two consensus disease activity indexes: the EULAR Sjögren’s Syndrome Patients Reported Index (ESSPRI), a patient-administered questionnaire to assess subjective features, and the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), a systemic activity index to assess systemic complications. Both indexes have good correlations with existing scores and also global evaluation of disease activity by physician for ESSDAI and by patient for ESSPRI. In addition, ESSDAI had a good sensitivity to change and detects changes more accurately, when compared to other scores. These both indexes are simple and aimed to be used for both clinical trials and clinical practice. They are currently being validated for that purpose.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, 3rd, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159(2):174–81.

    Article  PubMed  CAS  Google Scholar 

  2. Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Cyclosporin A (CyA) in primary Sjogren’s syndrome: a double blind study. Ann Rheum Dis. 1986;45(9):732–5.

    Article  PubMed  CAS  Google Scholar 

  3. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360–4.

    Article  PubMed  CAS  Google Scholar 

  4. Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren’s syndrome. J Rheumatol. 1998;25(5):896–9.

    PubMed  CAS  Google Scholar 

  5. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade In Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–6.

    Article  PubMed  CAS  Google Scholar 

  6. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240–5.

    Article  PubMed  CAS  Google Scholar 

  7. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjogren’s syndrome, April 10–11, 2003, Bethesda, Maryland, USA. J Rheumatol. 2005;32(1):143–9.

    PubMed  Google Scholar 

  8. Bowman SJ, Pillemer S, Jonsson R, Asmussen K, Vitali C, Manthorpe R, et al. Revisiting Sjogren’s syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) 2001;40(10):1180–8.

    Article  CAS  Google Scholar 

  9. Asmussen KH, Bowman SJ. Outcome measures in Sjogren’s syndrome. Rheumatology (Oxford) 2001;40(10):1085–8.

    Article  CAS  Google Scholar 

  10. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52(9):2740–50.

    Article  PubMed  CAS  Google Scholar 

  11. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Ann Rheum Dis. 2007;66(3):351–7.

    Article  PubMed  CAS  Google Scholar 

  12. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4.

    Article  PubMed  CAS  Google Scholar 

  13. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57(2):310–7.

    Article  PubMed  CAS  Google Scholar 

  14. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64(6):958–60.

    Article  PubMed  CAS  Google Scholar 

  15. Meijer JM, Vissink A, Meiners PM, Spijkervet FK, Kallenberg CG, Boostma H. Rituximab treatment in primary Sjögren’s syndrome: a double-blind controlled trial. Arthritis Rheum. 2008;58(9 Suppl):S430–1.

    Google Scholar 

  16. Meijer J, Meiners P, Vissink A, Spijkervet F, Abdulahad W, Kamminga N, et al. Effective rituximab treatment in primary Sjogren’s syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004;43(6):758–64.

    Article  CAS  Google Scholar 

  18. Bowman SJ, Booth DA, Platts RG, Field A, Rostron J. Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren’s syndrome. J Rheumatol. 2003;30(6):1259–66.

    PubMed  Google Scholar 

  19. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjogren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56(7):2223–31.

    Article  PubMed  Google Scholar 

  20. Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, et al. Sjogren’s systemic clinical activity index (SCAI)—a systemic disease activity measure for use in clinical trials in primary Sjogren’s syndrome. Rheumatology (Oxford) 2007;46(12):1845–51.

    Article  CAS  Google Scholar 

  21. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447–58.

    PubMed  CAS  Google Scholar 

  22. Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Boostma H, et al. Accurate detection of changes in disease activity in primary Sjogren’s syndrome by the European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken). 2010;62(4):551–8.

    Article  Google Scholar 

  23. Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis. 1998;57(1):20–4.

    Article  PubMed  CAS  Google Scholar 

  24. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70(6):968–92.

    Google Scholar 

  25. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis. 2009;69(6):1103–9.

    Google Scholar 

  26. Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, et al. The Sjogren’s syndrome damage index—a damage index for use in clinical trials and observational studies in primary Sjogren’s syndrome. Rheumatology (Oxford) 2008;47(8):1193–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistance Publique-Hopitaux de Paris, Hôpital Bicêtre, Department of Rheumatology, Institut Pour la Santé et la Recherche Médicale (INSERM) U 802, Université Paris-Sud 11, Le Kremlin Bicêtre, France

    Raphaèle Seror & Xavier Mariette

  2. Centre d’Epidomiologie Clinique, INSERM U738, Hôpital Hotel Dieu, Paris, France

    Philippe Ravaud

  3. Section of Rheumatology, Department of Internal Medicine, Villamarina Hospital, Piombino, Italy

    Claudio Vitali

  4. Department of Rheumatology, University Hospitals Birmingham, Birmingham, England

    Simon J. Bowman

Authors
  1. Raphaèle Seror
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Ravaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudio Vitali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simon J. Bowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xavier Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raphaèle Seror .

Editor information

Editors and Affiliations

  1. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Robert I. Fox

  2. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Carla M. Fox

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Seror, R., Ravaud, P., Vitali, C., Bowman, S.J., Mariette, X. (2011). Looking into the Future—The EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogren’s Syndrome. In: Fox, R., Fox, C. (eds) Sjögren’s Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-957-4_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-957-4_30

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-956-7

  • Online ISBN: 978-1-60327-957-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation